March 31, 2001 |
Ivax Corp. faces a revived legal challenge to its generic version of the top-selling Taxol cancer drug, after a federal appeals court told a trial judge to reexamine the Food and Drug Administration's approval of the Ivax product. The ruling is the latest in a multifaceted legal fight involving Ivax, Taxol manufacturer Bristol-Myers Squibb Co. and American BioScience Inc., which says it has a patented method to reduce the drug's side effects. The U.S. Court of Appeals for the D.C.
October 18, 2000 |
American BioScience Inc., owner of a patent on Bristol-Myers Squibb Co.'s cancer-treatment drug Taxol, has sued the Food and Drug Administration for the second time over its approval of Ivax Corp.'s generic version of the drug. Bristol-Myers, Ivax and Santa Monica-based American BioScience also are fighting in federal courts in New York and Washington and in a Florida state court, with the FDA a defendant in the Washington suit.
October 4, 2000 |
A federal judge cleared the way for Ivax Corp. to sell a generic version of Bristol-Myers Squibb Co.'s breast cancer drug Taxol. U.S. District Judge Colleen Kollar-Kotelly in Washington rejected a request by Santa Monica-based American BioScience Inc. that was aimed at blocking the generic version.
September 15, 2000 |
A federal appeals court in San Francisco has denied a petition from American BioScience Inc. that had threatened to delay Ivax Corp.'s plans to sell a generic form of Taxol, the world's best-selling cancer drug that is exclusively marketed by drug giant Bristol-Myers Squibb Co. The U.S. 9th Circuit Court of Appeals refused to stay an earlier decision by a U.S. district judge that was favorable to Ivax.
September 12, 2000 |
Bristol-Myers Squibb Co. opened a second front Monday in its effort to maintain a monopoly over sales of the cancer-fighting drug Taxol, asking a New York court to intervene in a case in which the giant pharmaceutical company faced an unfavorable ruling from the U.S. District Court in Los Angeles last week. Bristol-Myers, which sells about $1 billion of Taxol annually in the U.S.
September 8, 2000 |
Bristol-Myers Squibb Co. and Santa Monica-based American BioScience Inc. were given six days to try to stop a federal judge's order that could clear the way for a generic version of Bristol-Myers' breast cancer drug Taxol. U.S. District Judge William Matthew Byrne Jr. in Los Angeles said he would delay until Wednesday an order he issued this week that would force Bristol-Myers to remove American BioScience's Taxol-related patent from the Food and Drug Administration's list of valid patents.